Skip to main content
OpenTrials
Completed

NCT Number: NCT04934865

Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

Evaluation of patient's proportion, whose management care has been modified at least once and specially by Moovcare® Lung application at 12 and 24 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chu Argenteuil, Argenteuil, France

Loading trial locations.

About this study

Primary objective of the study:

The primary objective is a clinical one and is to evaluate the proportion of patients, whose management care has been modified at least once and specially by Moovcare® Lung application at 12 and 24 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with lung cancer at any diagnostic stage and histology.
  • Patient willing to use the follow-up setting with Moovcare® Lung apps.
  • Age ≥ 18 years.
  • Patient received anti-cancer treatment (surgery, chemotherapy, radiation (stereotaxy or not) or radio-chemotherapy association ended less than 12 weeks (Cohort 1 post-treatment); or during maintenance treatment or consolidation by chemotherapy or targeted therapy, or by immunotherapy initiated less than 12 weeks (Cohort 2 during treatment).
  • Imaging tumor evaluation less than 12 weeks showing disease control (response or stability according to RECIST 1.1 criteria).
  • Patient with symptomatic score on Moovcare® Lung apps less than 7.
  • Patient (or relatives) with internet access, a personnal e-mail box and a smartphone.
  • Patient with social security affiliation.
  • Signed informed consent form.

Exclusion criteria

  • Patient with progression after the first evaluation of initial treatment.
  • Pregnancy and breast-feeding.
  • Patient under tutorship or guardianship.
  • Dementia, mental alteration or psychiatric pathology influencing patient consent procedure and/or protocol observance and study follow-up.
  • Patient enable to protocol follow-up for psychological, social, familial or geographical reasons.

Treatment and study plan

Patients treated for their lung cancer.

Device

In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.

In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator.

Primary outcomes

  1. Proportion of patients.

    Time frame: 24 months

    Proportion of patients whose care management was modified at least once and specifically by Moovcare® Lung application at months.

  2. Proportion of patients.

    Time frame: 12 months

    Proportion of patients whose care management was modified at least once and specifically by Moovcare® Lung application at 12 months.

Secondary outcomes

  1. Clinical aspects : date of consultation.

    Time frame: 24 months

    Interval between the date of early consultation or early scan and the date of the scheduled consultation or scan.

  2. Clinical aspects : Number of unscheduled hospitalizations.

    Time frame: 24 months

    Number of unscheduled hospitalizations.

  3. Clinical aspects : Duration of unscheduled hospitalizations.

    Time frame: 24 months

    Duration of unscheduled hospitalizations.

  4. Clinical aspects : Number of overall hospitalizations.

    Time frame: 24 months

    Number of overall hospitalizations.

  5. Clinical aspects : Duration of overall hospitalizations.

    Time frame: 24 months

    Number of overall hospitalizations.

  6. Clinical aspects : Quality of life.

    Time frame: Every 3 months until 24 months

    Quality of life criteria with EORTC QLQ-C30 questionnaire scale.

  7. Clinical aspects : Overall survival over the entire follow-up.

    Time frame: 24 months

    Overall survival over the entire follow-up.

  8. Organizational aspects : number of stakeholders

    Time frame: 24 months

    Number of stakeholders on the application, number of stakeholders specifically recruited for the application and type of stakeholders.

  9. Organizational aspects : Time for each investigating center

    Time frame: 24 months

    Calculation of the time spent to set up the protocol and the application for each investigating center.

  10. Organizational aspects : Functioning and processing of alerts :

    Time frame: 24 months

    Time spent to register patients.

  11. Organizational aspects : Functioning and processing of alerts :

    Time frame: 24 months

    Total number of alerts, rate of alerts handled by the health care team.

  12. Organizational aspects : Functioning and processing of alerts :

    Time frame: 24 months

    Number of alerts that led to an early consultation: processing time, type of provider(s), number of alerts that led to further investigation and the type of investigation: processing time, type of provider(s), rate of alerts that led to a change in management.

  13. Organizational aspects : Functioning and processing of alerts :

    Time frame: 24 months

    Relevant post-alert management time, as well as the number of stakeholders on the application, type of stakeholders.

  14. Organizational aspects : Patient satisfaction.

    Time frame: 3, 6, 12, 18 and 24 months of use of the application

    The degree of patient satisfaction will be evaluated with a satisfaction questionnaire. A form to be filled in after 3, 6, 12, 18 and 24 months of use of the application.

  15. Organizational aspects : Satisfaction of the care teams at 6 months follow-up.

    Time frame: 6 months follow-up

    Physician satisfaction: the satisfaction of all doctors involved will be evaluated with a questionnaire to be filled in (Questionnaire Satisfaction Médecins).

    Staff satisfaction: the satisfaction of all staff involved (coordinating nurses, secretaries or other categories of staff) will be assessed with a questionnaire to be filled in (Questionnaire Satisfaction Collaborateur).

  16. Organizational aspects : Patient compliance.

    Time frame: 24 months

    The compliance will be evaluated by the ratio between the number of completed questionnaires and the invitation's number sent to complete them. Reasons of impossible connection (must be documented on medical records) will be subtracted from the calculation.

    The number of patients who voluntary abandoned the use of Moovcare® Lung medical device will be reduced considered as non-compliant.

  17. Organizational aspects : all secondary outcome measures

    Time frame: 12 months of follow-up

    above criteria will be assessed at 12 months of follow-up. This analysis will be done one year after inclusion of the last patient.

Sponsors and collaborators

Lead sponsor

Institut Curie

Other

Registry information

Official study title

Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

Acronym: REAL-MOOV-LUNG

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Jun 22, 2021
Registry last updated
Mar 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.